CANY
JNCE

Caxton Associates (New York)’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Caxton Associates (New York)’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,345
Closed -$87K – 648
2022
Q3 		$87K Buy
+37,345
New +$132K 0.01% 447
2020
Q4 		– Sell
-41,412
Closed -$338K – 359
2020
Q3 		$338K Buy
+41,412
New +$257K 0.04% 177
2020
Q1 		– Sell
-56,029
Closed -$489K – 637
2019
Q4 		$489K Buy
+56,029
New +$303K 0.07% 176

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Caxton Associates (New York)'s JNCE Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 37,345 shares — an estimated $87K sold.

Caxton Associates (New York) first reported a position in JNCE in Q4 2019 and held it in 3 quarters. The position peaked at $489K in Q4 2019. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 37,345 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $87K.
  • Caxton Associates (New York) first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Caxton Associates (New York)'s Jounce Therapeutics, Inc. Common Stock position peaked at $489K in Q4 2019.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.